Form 4 for ALNY ALNYLAM PHARMACEUTICALS, INC.
Accepted 2024-02-29 00:00:00 ET · period of report 2024-02-27 · accession 0001735276-24-000017 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-02-29 | 2024-02-28 | ALNY | Garg Pushkal | CMO, EVP Dev, Med Affairs | S - Sale+OE | $155.30 | -574 | 8,666 | -6% | -$89.1K |
| D | 2024-02-29 | 2024-02-27 | ALNY | Garg Pushkal | CMO, EVP Dev, Med Affairs | M - OptEx | $0.00 | +1,908 | 9,240 | +26% | $0 |
| D | 2024-02-29 | 2024-02-27 | ALNY | Garg Pushkal | CMO, EVP Dev, Med Affairs | M - OptEx | $0.00 | -1,908 | 3,816 | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-28 | S | D | 17 | $157.30 | 8,667 | D | — | — | (F5) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $157.01 to $157.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 2 | Common | Common Stock | 2024-02-28 | S | D | 115 | $156.38 | 8,684 | D | — | — | (F4) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $155.96 to $156.91. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 3 | Common | Common Stock | 2024-02-28 | S | D | 194 | $155.45 | 8,799 | D | — | — | (F3) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $154.95 to $155.95. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 4 | Common | Common Stock | 2024-02-28 | S | D | 247 | $154.54 | 8,993 | D | — | — | (F2) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $153.94 to $154.94. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 5 | Common | Common Stock | 2024-02-27 | M | A | 1,908 | $0.00 | 9,240 | D | — | — | |
| 6 | Common | Common Stock | 2024-02-28 | S | D | 1 | $158.09 | 8,666 | D | — | — | |
| 7 | Derivative | Restricted Stock Units | 2024-02-27 | M | D | 1,908 | $0.00 | 3,816 | D | — · — to — | 1,908 Common Stock | (F8) Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. (F9) On February 27, 2023, the reporting person was granted 5,724 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2024, the first tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4. |